Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) were down 6.8% during trading on Thursday . The stock traded as low as $15.38 and last traded at $15.25. Approximately 867,793 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 1,409,162 shares. The stock had previously closed at $16.36.
Ginkgo Bioworks Trading Down 13.9 %
The company’s fifty day moving average price is $10.73. The stock has a market cap of $809.61 million, a P/E ratio of -1.08 and a beta of 1.16.
Hedge Funds Weigh In On Ginkgo Bioworks
Several institutional investors have recently added to or reduced their stakes in the stock. Forbes J M & Co. LLP grew its position in Ginkgo Bioworks by 461.4% during the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company’s stock valued at $6,891,000 after buying an additional 576,732 shares during the period. Erste Asset Management GmbH bought a new position in Ginkgo Bioworks during the third quarter worth about $4,075,000. Jacobs Levy Equity Management Inc. bought a new position in Ginkgo Bioworks during the third quarter worth about $2,282,000. Charles Schwab Investment Management Inc. boosted its position in Ginkgo Bioworks by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company’s stock worth $2,295,000 after purchasing an additional 17,372 shares during the period. Finally, PFG Investments LLC bought a new position in Ginkgo Bioworks during the third quarter worth about $1,541,000. Institutional investors own 78.63% of the company’s stock.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- Investing in Travel Stocks Benefits
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- What is an Earnings Surprise?
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- What is a Stock Market Index and How Do You Use Them?
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
